Recent advances in microparticle and nanoparticle delivery vehicles for mucosal vaccination

Current Topics in Microbiology and Immunology

Volumn 354, Issue 1, 2012, Pages 75-99

  McNeela, E A ^a   Lavelle, E C ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ADHESIN; CALCIUM CHLORIDE; CALCIUM PHOSPHATE; CHITOSAN; CHOLERA VACCINE; CITRATE SODIUM; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA TOXOID; DNA VACCINE; DRUG VEHICLE; HEPATITIS B VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; LECTIN; MACROGOL; MALARIA VACCINE; MICROPARTICLE; MONOCLONAL ANTIBODY; NANOPARTICLE; PERTUSSIS VACCINE; PHOSPHORYLCHOLINE; POLYGLACTIN; POLYLACTIC ACID; POLYMER; POLYVINYL ALCOHOL; ROTAVIRUS VACCINE; SALMONELLOSIS VACCINE; SODIUM DIHYDROGEN PHOSPHATE; TETANUS TOXOID; UNCLASSIFIED DRUG; WART VIRUS VACCINE;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; BIODEGRADABILITY; CELLULAR IMMUNITY; CHLAMYDIASIS; CHOLERA; DRUG ADMINISTRATION ROUTE; DRUG ADSORPTION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STABILITY; DRUG UPTAKE; ENTERIC COATED TABLET; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; IMMUNOSTIMULATION; MALARIA; MICROENCAPSULATION; MICROFOLD CELL; MUCOSAL IMMUNITY; MULTIPLE CYCLE TREATMENT; NONHUMAN; PAPILLOMAVIRUS INFECTION; PERTUSSIS; POLYMERIZATION; PRIORITY JOURNAL; REVIEW; ROTAVIRUS INFECTION; SALMONELLOSIS;

ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; MUCOUS MEMBRANE; NANOPARTICLES; VACCINATION;

EID: 84856143228     PISSN: 0070217X     EISSN: None     Source Type: Book Series    
DOI: 10.1007/82_2011_140     Document Type: Review

References (161)

1. Aguado MT, Lambert PH (1992) Controlled-release vaccines-biodegradable polylactide/polyglycolide (PL/PG) microspheres as antigen vehicles. Immunobiology 184:113-125
2. Akagi T, Kawamura M, Ueno M et al (2003) Mucosal immunization with inactivated HIV-1-capturing nanospheres induces a significant HIV-1-specific vaginal antibody response in mice. J Med Virol 69:163-172 (Pubitemid 36068870)
3. Allaoui-Attarki K, Pecquet S, Fattal E et al (1997) Protective immunity against Salmonella typhimurium elicited in mice by oral vaccination with phosphorylcholine encapsulated in poly(DL-lactide-co-glycolide) microspheres. Infect Immun 65:853-857 (Pubitemid 27087981)
4. Almeida AJ, Alpar HO (1996) Nasal delivery of vaccines. J Drug Target 3:455-467 (Pubitemid 26280642)
5. Ando S, Putnam D, Pack DW et al (1999) PLGA microspheres containing plasmid DNA: preservation of supercoiled DNA via cryopreparation and carbohydrate stabilization. J Pharm Sci 88:126-130 (Pubitemid 29037379)
6. Beier R, Gebert A (1998) Kinetics of particle uptake in the domes of Peyer's patches. Am J Physiol 275:G130-G137
7. Bejon P, Lusingu J, Olotu A et al (2008) Efficacy of RTS, S/AS01E vaccine against malaria in children 5 to 17 months of age. N Engl J Med 359:2521-2532
8. Boland G, Beran J, Lievens M et al (2004) Safety and immunogenicity profile of an experimental hepatitis B vaccine adjuvanted with AS04. Vaccine 23:316-320 (Pubitemid 39463048)
9. Bowman K, Leong KW (2006) Chitosan nanoparticles for oral drug and gene delivery. Int J Nanomed 1:117-128
10. Brandtzaeg P, Johansen F-E (2008) The mucosal B-cell system. In: Vajdy M (ed) Immunity against mucosal pathogens. Springer-Verlag, New York, pp 33-76
11. Brayden DJ (2001) Oral vaccination in man using antigens in particles: current status. Eur J Pharm Sci 14:183-189 (Pubitemid 32884313)
12. Brooking J, Davis SS, Illum L (2001) Transport of nanoparticles across the rat nasal mucosa. J Drug Target 9:267-279 (Pubitemid 32776362)
13. Cahill ES, O'Hagan DT, Illum L et al (1995) Immune responses and protection against Bordetella pertussis infection after intranasal immunization of mice with filamentous haemagglutinin in solution or incorporated in biodegradable microparticles. Vaccine 13:455-462
14. Carcaboso AM, Hernandez RM, Igartua M et al (2003) Immune response after oral administration of the encapsulated malaria synthetic peptide SPf66. Int J Pharm 260:273-282 (Pubitemid 36773924)
15. Carcaboso AM, Hernandez RM, Igartua M et al (2004) Potent, long lasting systemic antibody levels and mixed Th1/Th2 immune response after nasal immunization with malaria antigen loaded PLGA microparticles. Vaccine 22:1423-1432 (Pubitemid 38446918)
16. Cario E, Rosenberg IM, Brandwein SL et al (2000) Lipopolysaccharide activates distinct signaling pathways in intestinal epithelial cell lines expressing Toll-like receptors. J Immunol 164:966-972 (Pubitemid 30043724)
17. Carpenter ZK, Williamson ED, Eyles JE (2005) Mucosal delivery of microparticle encapsulated ESAT-6 induces robust cell-mediated responses in the lung milieu. J Control Release 104:67-77 (Pubitemid 40615236)
18. Chabot S, Wagner JS, Farrant S et al (2006) TLRs regulate the gatekeeping functions of the intestinal follicle-associated epithelium. J Immunol 176:4275-4283 (Pubitemid 44264407)
19. Challacombe SJ, Rahman D, Jeffery H et al (1992) Enhanced secretory IgA and systemic IgG antibody responses after oral immunization with biodegradable microparticles containing antigen. Immunology 76:164-168
20. Chen F, Zhang ZR, Yuan F et al (2008) In vitro and in vivo study of N-trimethyl chitosan nanoparticles for oral protein delivery. Int J Pharm 349:226-233 (Pubitemid 350299699)
21. Chourasia MK, Jain SK (2003) Pharmaceutical approaches to colon targeted drug delivery systems. J Pharm Pharm Sci 6:33-66 (Pubitemid 37207241)
22. Clark MA, Blair H, Liang L et al (2001) Targeting polymerised liposome vaccine carriers to intestinal M cells. Vaccine 20:208-217 (Pubitemid 32905334)
23. Cleland JL (1999) Single-administration vaccines: controlled-release technology to mimic repeated immunizations. Trends Biotechnol 17:25-29 (Pubitemid 29246023)
24. Conway MA, Madrigal-Estebas L, McClean S et al (2001) Protection against Bordetella pertussis infection following parenteral or oral immunization with antigens entrapped in biodegradable particles: effect of formulation and route of immunization on induction of Th1 and Th2 cells. Vaccine 19:1940-1950 (Pubitemid 32178342)
25. Coombes AG, Lavelle EC, Davis SS (1999) Biodegradable lamellar particles of poly(lactide) induce sustained immune responses to a single dose of adsorbed protein. Vaccine 17: 2410-2422 (Pubitemid 29268364)
26. Cranage MP, Manoussaka M (2009) Modern mucosal vaccines, adjuvants and microbicides. Expert Rev Anti Infect Ther 7:21-23
27. Cu Y, Saltzman WM (2009) Controlled surface modification with poly(ethylene)glycol enhances diffusion of PLGA nanoparticles in human cervical mucus. Mol Pharm 6:173-181
28. Czerkinsky C, Holmgren J (2011) Mucosal delivery routes for optimal immunization: targeting immunity to the right tissues. Curr Top Microbiol Immunol (in press)
29. Dailey LA, Wittmar M, Kissel T (2005) The role of branched polyesters and their modifications in the development of modern drug delivery vehicles. J Control Release 101:137-149 (Pubitemid 39600978)
30. Damge C, Aprahamian M, Marchais H et al (1996) Intestinal absorption of PLAGA microspheres in the rat. J Anat 189(Pt 3):491-501 (Pubitemid 27011001)
31. Dea-Ayuela MA, Rama-Iniguez S, Torrado-Santiago S et al (2006) Microcapsules formulated in the enteric coating copolymer Eudragit L100 as delivery systems for oral vaccination against infections by gastrointestinal nematode parasites. J Drug Target 14:567-575 (Pubitemid 44592890)
32. Delgado A, Lavelle EC, Hartshorne M et al (1999) PLG microparticles stabilised using enteric coating polymers as oral vaccine delivery systems. Vaccine 17:2927-2938 (Pubitemid 29323021)
33. Desai MP, Labhasetwar V, Amidon GL et al (1996) Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharm Res 13:1838-1845 (Pubitemid 27034116)
34. Dong Z, Yang Z, Wang C (2005) Expression of TLR2 and TLR4 messenger RNA in the epithelial cells of the nasal airway. Am J Rhinol 19:236-239 (Pubitemid 40936424)
35. Douce G, Giannelli V, Pizza M et al (1999) Genetically detoxified mutants of heat-labile toxin from Escherichia coli are able to act as oral adjuvants. Infect Immun 67:4400-4406 (Pubitemid 29400413)
36. Elamanchili P, Diwan M, Cao M et al (2004) Characterization of poly(D, L-lactic-co-glycolic acid) based nanoparticulate system for enhanced delivery of antigens to dendritic cells. Vaccine 22:2406-2412 (Pubitemid 38757337)
37. Eldridge JH, Meulbroek JA, Staas JK et al (1989) Vaccine-containing biodegradable microspheres specifically enter the gut-associated lymphoid tissue following oral administration and induce a disseminated mucosal immune response. Adv Exp Med Biol 251: 191-202
38. Eldridge JH, Hammond CJ, Meulbroek JA, Staas JK et al (1990) Controlled vaccine release in the gut-associated lymphoid tissues. I. Orally administered biodegradable microspheres target the Peyer's patches. J Controlled Release 11:205-214 (Pubitemid 20070098)
39. Fattal E, Pecquet S, Couvreur P et al (2002) Biodegradable microparticles for the mucosal delivery of antibacterial and dietary antigens. Int J Pharm 242:15-24
40. Florence AT, Hillery AM, Hussain N et al (1995) Factors affecting the oral uptake and translocation of polystyrene nanoparticles: histological and analytical evidence. J Drug Target 3:65-70
41. Florindo HF, Pandit S, Goncalves LM et al (2009) New approach on the development of a mucosal vaccine against strangles: systemic and mucosal immune responses in a mouse model. Vaccine 27:1230-1241
42. Foged C, Brodin B, Frokjaer S et al (2005) Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model. Int J Pharm 298:315-322 (Pubitemid 40910735)
43. Foster N, Hirst BH (2005) Exploiting receptor biology for oral vaccination with biodegradable particulates. Adv Drug Deliv Rev 57:431-450 (Pubitemid 39550969)
44. Foster N, Clark MA, Jepson MA et al (1998) Ulex europaeus 1 lectin targets microspheres to mouse Peyer's patch M-cells in vivo. Vaccine 16:536-541 (Pubitemid 28044172)
45. Fujimura Y (2000) Evidence of M cells as portals of entry for antigens in the nasopharyngeal lymphoid tissue of humans. Virchows Arch 436:560-566 (Pubitemid 30406638)
46. Fujimura Y, Akisada T, Harada T et al (2006) Uptake of microparticles into the epithelium of human nasopharyngeal lymphoid tissue. Med Mol Morphol 39:181-186 (Pubitemid 46013055)
47. Gallichan WS, Woolstencroft RN, Guarasci T et al (2001) Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract. J Immunol 166:3451-3457 (Pubitemid 33117348)
48. Garinot M, Fievez V, Pourcelle V et al (2007) PEGylated PLGA-based nanoparticles targeting M cells for oral vaccination. J Control Release 120:195-204 (Pubitemid 47061488)
49. Giannasca PJ, Giannasca KT, Falk P et al (1994) Regional differences in glycoconjugates of intestinal M cells in mice: potential targets for mucosal vaccines. Am J Physiol 267: G1108-G1121
50. Giudice EL, Campbell JD (2006) Needle-free vaccine delivery. Adv Drug Deliv Rev 58:68-89
51. Gref R, Minamitake Y, Peracchia MT et al (1994) Biodegradable long-circulating polymeric nanospheres. Science 263:1600-1603 (Pubitemid 24128361)
52. Gupta RK, Singh M, O'Hagan DT (1998) Poly(lactide-co-glycolide) microparticles for the development of single-dose controlled-release vaccines. Adv Drug Deliv Rev 32:225-246 (Pubitemid 28267411)
53. Gupta PN, Khatri K, Goyal AK et al (2007) M-cell targeted biodegradable PLGA nanoparticles for oral immunization against hepatitis B. J Drug Target 15:701-713 (Pubitemid 350201323)
54. Gutierro I, Hernandez RM, Igartua M et al (2002) Size dependent immune response after subcutaneous, oral and intranasal administration of BSA loaded nanospheres. Vaccine 21: 67-77 (Pubitemid 35351352)
55. Haltner E, Easson JH, Lehr CM (1997) Lectins and bacterial invasion factors for controlling endo-and transcytosis of bioadhesive drug carrier systems. Eur J Pharm Biopharm 44:3-13 (Pubitemid 28298770)
56. Hamashin C, Spindler L, Russell S et al (2003) Identification of novel small-molecule Ulex europaeus I mimetics for targeted drug delivery. Bioorg Med Chem 11:4991-4997 (Pubitemid 37352986)
57. He Q, Mitchell AR, Johnson SL et al (2000) Calcium phosphate nanoparticle adjuvant. Clin Diagn Lab Immunol 7:899-903 (Pubitemid 32244486)
58. He Q, Mitchell A, Morcol T et al (2002) Calcium phosphate nanoparticles induce mucosal immunity and protection against herpes simplex virus type 2. Clin Diagn Lab Immunol 9:1021-1024 (Pubitemid 34988469)
59. Heritage PL, Brook MA, Underdown BJ et al (1998) Intranasal immunization with polymer-grafted microparticles activates the nasal-associated lymphoid tissue and draining lymph nodes. Immunology 93:249-256 (Pubitemid 28088293)
60. Herrmann JE, Chen SC, Jones DH et al (1999) Immune responses and protection obtained by oral immunization with rotavirus VP4 and VP7 DNA vaccines encapsulated in microparticles. Virology 259:148-153 (Pubitemid 29391765)
61. Hussain N, Florence AT (1998) Utilizing bacterial mechanisms of epithelial cell entry: invasin-induced oral uptake of latex nanoparticles. Pharm Res 15:153-156 (Pubitemid 28080884)
62. Illum L, Farraj NF, Davis SS (1994) Chitosan as a novel nasal delivery system for peptide drugs. Pharm Res 11:1186-1189 (Pubitemid 24259861)
63. Iqbal M, Lin W, Jabbal-Gill I et al (2003) Nasal delivery of chitosan-DNA plasmid expressing epitopes of respiratory syncytial virus (RSV) induces protective CTL responses in BALB/c mice. Vaccine 21:1478-1485 (Pubitemid 36263189)
64. Jaganathan KS, Vyas SP (2006) Strong systemic and mucosal immune responses to surface-modified PLGA microspheres containing recombinant hepatitis B antigen administered intranasally. Vaccine 24:4201-4211
65. Janeway CA Jr, Medzhitov R (2002) Innate immune recognition. Annu Rev Immunol 20:197-216 (Pubitemid 34293424)
66. Jani P, Halbert GW, Langridge J, Florence AT (1990) Nanoparticle uptake by the rat gastrointestinal mucosa: quantitation and particle size dependency. J Pharm Pharmacol 42:821-826
67. Jani PU, Florence AT, McCarthy DE (1992) Further histological evidence of the gastrointestinal absorption of polystyrene nanospheres in the rat. Int J Pharm 84:245-252
68. Jepson MA, Simmons NL, O'Hagan DT et al (1993a) Comparison of poly(DL-lactide-co-glycolide) and polystyrene microsphere targeting to intestinal M cells. J Drug Target 1:245-249
69. Jepson MA, Simmons NL, Savidge TC et al (1993b) Selective binding and transcytosis of latex microspheres by rabbit intestinal M cells. Cell Tissue Res 271:399-405 (Pubitemid 23095069)
70. Jones DH, McBride BW, Thornton C et al (1996) Orally administered microencapsulated Bordetella pertussis fimbriae protect mice from B. pertussis respiratory infection. Infect Immun 64:489-494 (Pubitemid 26032819)
71. Jung T, Kamm W, Breitenbach A et al (2001) Tetanus toxoid loaded nanoparticles from sulfobutylated poly(vinyl alcohol)-graft-poly(lactide-co- glycolide): evaluation of antibody response after oral and nasal application in mice. Pharm Res 18:352-360 (Pubitemid 32595824)
72. Kaneko H, Bednarek I, Wierzbicki A et al (2000) Oral DNA vaccination promotes mucosal and systemic immune responses to HIV envelope glycoprotein. Virology 267:8-16 (Pubitemid 30094148)
73. Kang ML, Cho CS, Yoo HS (2009) Application of chitosan microspheres for nasal delivery of vaccines. Biotechnol Adv 27:857-865
74. Katz DE, DeLorimier AJ, Wolf MK et al (2003) Oral immunization of adult volunteers with microencapsulated enterotoxigenic Escherichia coli (ETEC) CS6 antigen. Vaccine 21: 341-346 (Pubitemid 36091922)
75. Kawamura M, Naito T, Ueno M et al (2002) Induction of mucosal IgA following intravaginal administration of inactivated HIV-1-capturing nanospheres in mice. J Med Virol 66:291-298 (Pubitemid 34111768)
76. Kazzaz J, Neidleman J, Singh M, Ott G, O'Hagan DT (2000) Novel anionic microparticles are a potent adjuvant for the induction of cytotoxic T lymphocytes against recombinant p55 gag from HIV-1. J Control Release 67:347-356 (Pubitemid 30303847)
77. Kazzaz J, Singh M, Ugozzoli M et al (2006) Encapsulation of the immune potentiators MPL and RC529 in PLG microparticles enhances their potency. J Control Release 110:566-573 (Pubitemid 43168189)
78. Kende M, Yan C, Hewetson J et al (2002) Oral immunization of mice with ricin toxoid vaccine encapsulated in polymeric microspheres against aerosol challenge. Vaccine 20:1681-1691 (Pubitemid 34169812)
79. Kerr JR (1999) Cell adhesion molecules in the pathogenesis of and host defence against microbial infection. Mol Pathol 52:220-230 (Pubitemid 29369208)
80. Kwon YJ, James E, Shastri N et al (2005) In vivo targeting of dendritic cells for activation of cellular immunity using vaccine carriers based on pH-responsive microparticles. Proc Natl Acad Sci USA 102:18264-18268 (Pubitemid 43011215)
81. Lai SK, O'Hanlon DE, Harrold S et al (2007) Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus. Proc Natl Acad Sci USA 104:1482-1487 (Pubitemid 46214616)
82. Lambert JS, Keefer M, Mulligan MJ et al (2001) A Phase I safety and immunogenicity trial of UBI microparticulate monovalent HIV-1 MN oral peptide immunogen with parenteral boost in HIV-1 seronegative human subjects. Vaccine 19:3033-3042 (Pubitemid 32324030)
83. Lambkin I, Pinilla C, Hamashin C et al (2003) Toward targeted oral vaccine delivery systems: selection of lectin mimetics from combinatorial libraries. Pharm Res 20:1258-1266 (Pubitemid 36951851)
84. Lavelle EC (2001) Targeted delivery of drugs to the gastrointestinal tract. Crit Rev Ther Drug Carrier Syst 18:341-386 (Pubitemid 32953899)
85. Lavelle EC (2005) Generation of improved mucosal vaccines by induction of innate immunity. Cell Mol Life Sci 62:2750-2770 (Pubitemid 41779945)
86. Li H, Willingham SB, Ting JP et al (2008) Cutting edge: inflammasome activation by alum and alum's adjuvant effect are mediated by NLRP3. J Immunol 181:17-21
87. Lin SY, Chen KS, Teng HH et al (2000) In vitro degradation and dissolution behaviours of microspheres prepared by three low molecular weight polyesters. J Microencapsul 17: 577-586
88. Lunsford L, McKeever U, Eckstein V et al (2000) Tissue distribution and persistence in mice of plasmid DNA encapsulated in a PLGA-based microsphere delivery vehicle. J Drug Target 8:39-50 (Pubitemid 30189692)
89. Luzardo-Alvarez A, Blarer N, Peter K et al (2005) Biodegradable microspheres alone do not stimulate murine macrophages in vitro, but prolong antigen presentation by macrophages in vitro and stimulate a solid immune response in mice. J Control Release 109:62-76 (Pubitemid 41737253)
90. Macpherson AJ, McCoy KD, Johansen FE et al (2008) The immune geography of IgA induction and function. Mucosal Immunol 1:11-22
91. Maloy KJ, Donachie AM, O'Hagan DT et al (1994) Induction of mucosal and systemic immune responses by immunization with ovalbumin entrapped in poly(lactide-co-glycolide) micro-particles. Immunology 81:661-667 (Pubitemid 24246520)
92. Matsuno K, Ezaki T, Kudo S et al (1996) A life stage of particle-laden rat dendritic cells in vivo: their terminal division, active phagocytosis, and translocation from the liver to the draining lymph. J Exp Med 183:1865-1878 (Pubitemid 26134327)
93. McClean S, Prosser E, Meehan E et al (1998) Binding and uptake of biodegradable poly-DL-lactide micro-and nanoparticles in intestinal epithelia. Eur J Pharm Sci 6:153-163 (Pubitemid 28164286)
94. McCluskie MJ, Weeratna RD, Krieg AM et al (2000) CpG DNA is an effective oral adjuvant to protein antigens in mice. Vaccine 19:950-957
95. Mestecky J, Russell MW (2009) Specific antibody activity, glycan heterogeneity and polyreactivity contribute to the protective activity of S-IgA at mucosal surfaces. Immunol Lett 124:57-62
96. Minne A, Louahed J, Mehauden S et al (2007) The delivery site of a monovalent influenza vaccine within the respiratory tract impacts on the immune response. Immunology 122:316-325 (Pubitemid 47556468)
97. Minor P (2009) Vaccine-derived poliovirus (VDPV): impact on poliomyelitis eradication. Vaccine 27:2649-2652
98. Misumi S, Masuyama M, Takamune N et al (2009) Targeted delivery of immunogen to primate m cells with tetragalloyl lysine dendrimer. J Immunol 182:6061-6070
99. Miyake A, Akagi T, Enose Y et al (2004) Induction of HIV-specific antibody response and protection against vaginal SHIV transmission by intranasal immunization with inactivated SHIV-capturing nanospheres in macaques. J Med Virol 73:368-377 (Pubitemid 38685742)
100. Moldoveanu Z, Novak M, Huang WQ et al (1993) Oral immunization with influenza virus in biodegradable microspheres. J Infect Dis 167:84-90 (Pubitemid 23002841)
101. Monie A, Hung CF, Roden R et al (2008) Cervarix: a vaccine for the prevention of HPV 16, 18-associated cervical cancer. Biologics 2:97-105
102. Monteleone I, Platt AM, Jaensson E et al (2008) IL-10-dependent partial refractoriness to Toll-like receptor stimulation modulates gut mucosal dendritic cell function. Eur J Immunol 38:1533-1547
103. Moore A, McGuirk P, Adams S et al (1995) Immunization with a soluble recombinant HIV protein entrapped in biodegradable microparticles induces HIV-specific CD8+ cytotoxic T lymphocytes and CD4+ Th1 cells. Vaccine 13:1741-1749 (Pubitemid 26013110)
104. Morcol T, Nagappan P, Nerenbaum L et al (2004) Calcium phosphate-PEG-insulin-casein (CAPIC) particles as oral delivery systems for insulin. Int J Pharm 277:91-97 (Pubitemid 38670424)
105. Muir A, Soong G, Sokol S et al (2004) Toll-like receptors in normal and cystic fibrosis airway epithelial cells. Am J Respir Cell Mol Biol 30:777-783 (Pubitemid 38736900)
106. Naisbett B, Woodley J (1994) The potential use of tomato lectin for oral drug delivery. 1. Lectin binding to rat small intestine in vitro. Int J Pharm 107:223-230 (Pubitemid 24182108)
107. Neutra MR, Kraehenbuhl JP (1992) Transepithelial transport and mucosal defence I: the role of M cells. Trends Cell Biol 2:134-138
108. Newman KD, Elamanchili P, Kwon GS et al (2002) Uptake of poly(D, L-lactic-co-glycolic acid) microspheres by antigen-presenting cells in vivo. J Biomed Mater Res 60:480-486
109. Nochi T, Takagi H, Yuki Y et al (2007) Rice-based mucosal vaccine as a global strategy for cold-chain-and needle-free vaccination. Proc Natl Acad Sci USA 104:10986-10991 (Pubitemid 47175213)
110. O'Hagan DT (1996) The intestinal uptake of particles and the implications for drug and antigen delivery. J Anat 189(Pt 3):477-482 (Pubitemid 27010998)
111. O'Hagan DT (1998) Recent advances in vaccine adjuvants for systemic and mucosal administration. J Pharm Pharmacol 50:1-10
112. O'Hagan DT, De Gregorio E (2009) The path to a successful vaccine adjuvant-'the long and winding road'. Drug Discov Today 14:541-551
113. O'Hagan DT, Singh M, Ulmer JB (2006) Microparticle-based technologies for vaccines. Methods 40:10-19 (Pubitemid 44415494)
114. Pappo J, Ermak TH, Steger HJ (1991) Monoclonal antibody-directed targeting of fluorescent polystyrene microspheres to Peyer's patch M cells. Immunology 73:277-280
115. Park TG, Lu W, Crotts G (1995) Importance of in vitro experimental conditions on protein release kinetics, stability and polymer degradation in protein encapsulated poly (D, L-lactic acid-co-glycolic acid) microspheres. J Controlled Release 33:211-222
116. Pun PB, Bhat AA, Mohan T et al (2009) Intranasal administration of peptide antigens of HIV with mucosal adjuvant CpG ODN coentrapped in microparticles enhances the mucosal and systemic immune responses. Int Immunopharmacol 9:468-477
117. Reece JC, Vardaxis NJ, Marshall JA et al (2001) Uptake of HIV and latex particles by fresh and cultured dendritic cells and monocytes. Immunol Cell Biol 79:255-263 (Pubitemid 32522174)
118. Roth-Walter F, Bohle B, Scholl I et al (2005) Targeting antigens to murine and human M-cells with Aleuria aurantia lectin-functionalized microparticles. Immunol Lett 100:182-188 (Pubitemid 41262018)
119. Roy K, Mao HQ, Huang SK et al (1999) Oral gene delivery with chitosan-DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat Med 5:387-391 (Pubitemid 29180575)
120. Russell-Jones GJ (2001) The potential use of receptor-mediated endocytosis for oral drug delivery. Adv Drug Deliv Rev 46:59-73
121. Rydell N, Stertman L, Stalenheim G et al (2006) Use of an oral diphtheria vaccine in human. Vaccine 24:5928-5930 (Pubitemid 44080357)
122. Saint-Lu N, Tourdot S, Razafindratsita A et al (2009) Targeting the allergen to oral dendritic cells with mucoadhesive chitosan particles enhances tolerance induction. Allergy 64:1003-1013
123. Salerno-Goncalves R, Pasetti MF, Sztein MB (2002) Characterization of CD8(F) effector T cell responses in volunteers immunized with Salmonella enterica serovar Typhi strain Ty21a typhoid vaccine. J Immunol 169:2196-2203 (Pubitemid 34857688)
124. Salman HH, Gamazo C, Agueros M, Irache JM (2007) Bioadhesive capacity and immunoad-juvant properties of thiamine-coated nanoparticles. Vaccine 25:8123-8132 (Pubitemid 350046324)
125. Salman HH, Irache JM, Gamazo C (2009) Immunoadjuvant capacity of flagellin and mannosamine-coated poly(anhydride) nanoparticles in oral vaccination. Vaccine 27: 4784-4790
126. Sass W, Dreyer HP, Seifert J (1990) Rapid insorption of small particles in the gut. Am J Gastroenterol 85:255-260 (Pubitemid 20090039)
127. Seong SY, Cho NH, Kwon IC et al (1999) Protective immunity of microsphere-based mucosal vaccines against lethal intranasal challenge with Streptococcus pneumoniae. Infect Immun 67:3587-3592 (Pubitemid 29291533)
128. Sharp FA, Ruane D, Claass B et al (2009) Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome. Proc Natl Acad Sci USA 106:870-875
129. Shimosato T, Tohno M, Kitazawa H et al (2005) Toll-like receptor 9 is expressed on follicle-associated epithelia containing M cells in swine Peyer's patches. Immunol Lett 98:83-89 (Pubitemid 40409822)
130. Shreedhar VK, Kelsall BL, Neutra MR (2003) Cholera toxin induces migration of dendritic cells from the subepithelial dome region to T-and B-cell areas of Peyer's patches. Infect Immun 71:504-509 (Pubitemid 36026055)
131. Singh M, Briones M, Ott G et al (2000) Cationic microparticles: A potent delivery system for DNA vaccines. Proc Natl Acad Sci USA 97:811-816 (Pubitemid 30070392)
132. Singla AK, Chawla M (2001) Chitosan: some pharmaceutical and biological aspects-an update. J Pharm Pharmacol 53:1047-1067 (Pubitemid 32754936)
133. Spit BJ, Hendriksen EG, Bruijntjes JP et al (1989) Nasal lymphoid tissue in the rat. Cell Tissue Res 255:193-198 (Pubitemid 19017922)
134. Tabata Y, Ikada Y (1988) Effect of the size and surface charge of polymer microspheres on their phagocytosis by macrophage. Biomaterials 9:356-362
135. Tabata Y, Inoue Y, Ikada Y (1996) Size effect on systemic and mucosal immune responses induced by oral administration of biodegradable microspheres. Vaccine 14:1677-1685 (Pubitemid 27041922)
136. Tacket CO, Reid RH, Boedeker EC et al (1994) Enteral immunization and challenge of volunteers given enterotoxigenic. E.coli CFA/II encapsulated in biodegradable microspheres. Vaccine 12:1270-1274 (Pubitemid 24325723)
137. Tafaghodi M, Sajadi Tabassi SA, Jaafari MR (2006) Induction of systemic and mucosal immune responses by intranasal administration of alginate microspheres encapsulated with tetanus toxoid and CpG-ODN. Int J Pharm 319:37-43 (Pubitemid 44051800)
138. Takahata H, Lavelle EC, Coombes AG et al (1998) The distribution of protein associated with poly(DL-lactide co-glycolide) microparticles and its degradation in simulated body fluids. J Control Release 50:237-246 (Pubitemid 28044118)
139. Tango M, Suzuki E, Gejyo F et al (2000) The presence of specialized epithelial cells on the bronchus-associated lymphoid tissue (BALT) in the mouse. Arch Histol Cytol 63:81-89 (Pubitemid 30202194)
140. Tharanathan RN, Kittur FS (2003) Chitin-the undisputed biomolecule of great potential. Crit Rev Food Sci Nutr 43:61-87 (Pubitemid 38552311)
141. Thiele L, Merkle HP, Walter E (2003) Phagocytosis and phagosomal fate of surface-modified microparticles in dendritic cells and macrophages. Pharm Res 20:221-228 (Pubitemid 36269728)
142. Thompson AH, McRoberts JG, Crowe SR et al (1999) Optimal induction of upper respiratory tract immunity to reovirus 1/L by combined upper and lower respiratory tract inoculation. Vaccine 17:1404-1415 (Pubitemid 29138807)
143. Tobio M, Gref R, Sanchez A et al (1998) Stealth PLA-PEG nanoparticles as protein carriers for nasal administration. Pharm Res 15:270-275 (Pubitemid 28144240)
144. Tobio M, Sanchez A, Vila A et al (2000) The role of PEG on the stability in digestive fluids and in vivo fate of PEG-PLA nanoparticles following oral administration. Colloids Surf B Biointerfaces 18:315-323
145. Ugozzoli M, O'Hagan DT, Ott GS (1998) Intranasal immunization of mice with herpes simplex virus type 2 recombinant gD2: the effect of adjuvants on mucosal and serum antibody responses. Immunology 93:563-571 (Pubitemid 28172630)
146. Vajdy M, O'Hagan DT (2001) Microparticles for intranasal immunization. Adv Drug Deliv Rev 51:127-141 (Pubitemid 32763077)
147. Van Broekhoven CL, Parish CR, Demangel C et al (2004) Targeting dendritic cells with antigen-containing liposomes: a highly effective procedure for induction of antitumor immunity and for tumor immunotherapy. Cancer Res 64:4357-4365 (Pubitemid 38802444)
148. Van Duin D, Medzhitov R, Shaw AC (2006) Triggering TLR signaling in vaccination. Trends Immunol 27:49-55 (Pubitemid 43083564)
149. Vila A, Sanchez A, Perez C, Alonso MJ (2002a) PLA-PEG nanospheres: new carriers for transmucosal delivery of proteins and plasmid DNA. Polym Adv Technol 13:851-858 (Pubitemid 36230239)
150. Vila A, Sanchez A, Tobio M et al (2002b) Design of biodegradable particles for protein delivery. J Control Release 78:15-24 (Pubitemid 34081849)
151. Vila A, Gill H, McCallion O et al (2004a) Transport of PLA-PEG particles across the nasal mucosa: effect of particle size and PEG coating density. J Control Release 98:231-244 (Pubitemid 38950733)
152. Vila A, Sanchez A, Evora C et al (2004b) PEG-PLA nanoparticles as carriers for nasal vaccine delivery. J Aerosol Med 17:174-185 (Pubitemid 38955679)
153. Vyas SP, Gupta PN (2007) Implication of nanoparticles/microparticles in mucosal vaccine delivery. Expert Rev Vaccines 6:401-418 (Pubitemid 46911603)
154. Wagner S, Lynch NJ, Walter W et al (2003) Differential expression of the murine mannose-binding lectins A and C in lymphoid and nonlymphoid organs and tissues. J Immunol 170:1462-1465 (Pubitemid 36139515)
155. Wang YY, Lai SK, Suk JS et al (2008) Addressing the PEG mucoadhesivity paradox to engineer nanoparticles that "slip" through the human mucus barrier. Angew Chem Int Ed Engl 47:9726-9729
156. Watts PJ, Davies MC, Melia CD (1990) Microencapsulation using emulsification/solvent evaporation: an overview of techniques and applications. Crit Rev Ther Drug Carrier Syst 7:235-259
157. Whittum-Hudson JA, An LL, Saltzman WM et al (1996) Oral immunization with
158. Woodle MC, Lasic DD (1992) Sterically stabilized liposomes. Biochim Biophys Acta 1113: 171-199
159. Yeh MK, Liu YT, Chen JL et al (2002) Oral immunogenicity of the inactivated Vibrio cholerae whole-cell vaccine encapsulated in biodegradable microparticles. J Control Release 82: 237-247
160. Yue Y, Xu W, Hu L et al (2009) Enhanced resistance to coxsackievirus B3-induced myocarditis by intranasal co-immunization of lymphotactin gene encapsulated in chitosan particle. Virology 386:438-447
161. Yuki Y, Tokuhara D, Nochi T et al (2009) Oral MucoRice expressing double-mutant cholera toxin A and B subunits induces toxin-specific neutralising immunity. Vaccine 27:5982-5988